Note: CLL17 is an investigator-initiated trial that the CLL17 page of the Imbruvica HCP site cites (Al-Sawaf et al., N Engl J Med 2025). These passages report the Imbruvica and venetoclax plus obinutuzumab arms. 1.608 is the prespecified noninferiority margin for the hazard ratio; the page does not state the observed hazard ratio.
How effective is Imbruvica vs ofatumumab in relapsed CLL (RESONATE)?
Applies to Adults with previously treated (relapsed or refractory) CLL/SLL